

pISSN 2288-6575 • eISSN 2288-6796 https://doi.org/10.4174/astr.2020.98.5.215 Annals of Surgical Treatment and Research

# Surgical impact on anxiety of patients with breast cancer: 12-month follow-up prospective longitudinal study

Jiyoung Kim<sup>1,\*</sup>, Juhee Cho<sup>2,\*</sup>, Se Kyung Lee<sup>3</sup>, Eun-Kyung Choi<sup>2</sup>, Im-Ryung Kim<sup>2</sup>, Jeong Eon Lee<sup>3</sup>, Seok Won Kim3, Seok-Jin Nam3

<sup>1</sup>Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea

<sup>2</sup>Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Purpose: Breast cancer diagnosis and treatment often produce stress in patients. Anxiety is one of the most prevalent psychological symptoms perceived by breast cancer patients. This study aims to evaluate the temporal patterns of anxiety and find factors associated with persistent anxiety during breast cancer treatment.

Methods: This is prospective cohort study. Between July 2010 and July 2011, we recruited patients with nonmetastatic breast cancer who were expected to receive adjuvant chemotherapy (n = 411) from 2 cancer hospitals in Seoul, Korea. Anxiety was measured using the Hospital Anxiety and Depression Scale.

Results: The mean age of the participants was 46.4 ± 7.9 years. Preoperatively, 44.5% (183 of 411) of the patients showed abnormal anxiety. The proportion of the abnormal anxiety group significantly decreased after surgery (P < 0.01) and this phenomenon continued until the 12-month follow-up point. Patients experienced renewed anxiety at 12 months when the main adjuvant therapies were finished. Socioeconomic factors were not associated with persistent anxiety. Pain, breast, and arm symptoms were significantly higher in the persistently abnormal group, especially at postoperative months 6 and 12. Conclusion: Surgery was a major relieving factor of anxiety, and patients who finished their main adjuvant treatment experienced renewed anxiety. Surgeons should be the main detectors and care-givers with respect to psychological distress in breast cancer patients. To reduce persistent anxiety, caring for the patient's physical symptoms is important. [Ann Surg Treat Res 2020;98(5):215-223]

Key Words: Anxiety, Breast neoplasms, Perioperative period, Surgery

#### INTRODUCTION

Treatments for breast cancer are long and complicated processes, including surgery, chemotherapy, radiotherapy, endocrine therapy, and target therapy. During the long period of treatment, breast cancer patients experience several diverse psychological distresses, such as depression, anxiety, pain, and social isolation. This psychological distress is a normal and adaptive reaction to unpleasant stimuli or threats. However, it sometimes persists in some patients to where it may damage the individual's quality of life (QoL) [1,2], adherence to treatment [3,4], and even clinical outcomes [5-7] in breast cancer. Therefore, the American College of Surgeons Commission on Cancer and National Comprehensive Cancer Network recommended that cancer patients be routinely screened for psychological distress during the cancer trajectory.

Received November 5, 2019, Revised February 8, 2020, Accepted February 20, 2020

#### Corresponding Author: Se Kyung Lee

Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea

**Tel:** +82-2-3410-0926, **Fax:** +82-2-3410-6982 **E-mail:** zzangdoc@gmail.com

**ORCID:** https://orcid.org/0000-0003-1630-1783

\*Jiyoung Kim and Juhee Cho contributed equally to this study as co-first authors.

Copyright © 2020, the Korean Surgical Society

(CC) Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

<sup>&</sup>lt;sup>3</sup>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea



Among psychological distresses, anxiety is very common and has been associated with cancer [1,2,8-12]. However, most studies examining psychological distress have been focused on depression, and the concerns about anxiety have been relatively small compared to depression.

We conducted this prospective longitudinal cohort study to determine the QoL and psychological distress of breast cancer patients who were newly diagnosed with their respective diseases. In this report, we evaluated the temporal patterns of anxiety in patients who underwent breast cancer operations using the Hospital Anxiety Depression Scale (HADS), and found factors associated with persistent anxiety during breast cancer treatment. The HADS [13] is a standardized 14-item self-assessment instrument for the evaluation of anxiety and depression in patients with nonpsychiatric and physical illness (Supplementary Table 1). It has been frequently used in cancer research as a validated, brief and effective screening tool [14]. This was used in this study because it can be easily assessed without proficiency and the Korean versions of the HADS has been validated [15].

#### **METHODS**

# Study design and population

This was a prospective longitudinal cohort study that followed consecutive newly diagnosed breast cancer patients 18 years and older from 2 different cancer hospitals in Seoul, Korea, between July 2010 and July 2011. Patients were asked to fill out preoperative questionnaires, and again at 2 weeks, 3 months, 6 months, and 12 months after surgery by themselves. If they had difficulties understanding or filling out the questionnaires, a nurse or trained research assistant helped them to complete the questionnaire.

We included patients who underwent breast cancer surgery with pathologic stage 0 to III in this study (n = 851). We excluded patients who received neo-adjuvant treatment and had secondary cancer, or who did not understand the purpose of the study or had psychotic disorders at the beginning of the survey. Ultimately, 432 patients (50.8%) agreed to participate in the study. For the analysis of this study for anxiety disorder, 7 patients who had recurrence or a second primary cancer during follow-up and 14 patients who did not have the information about anxiety were excluded. The final analysis included 411 patients (Fig. 1). This study was approved by the Institutional Review Boards (IRB No. SMC 2010-05-069), and all study participants provided written informed consent.

#### Measurement

Anxiety was assessed using the patient's completed HADS, which is frequently used as a screening tool for psychological distress in cancer patients. A study was conducted to

standardize the HADS for Koreans by Oh et al. [15], which demonstrated the validity and accessibility of the HADS, and we used this Korean version of the questionnaire for this study (Supplementary Table 2). There are 7 questions for the anxiety dimension in HADS (HADS-A) and each item is scored on a scale of 0 to 3, with a higher score indicating a more severe symptom. The scores can be categorized as: 0-7, normal; 8-10, borderline; and 11-21, abnormal. In this analysis, we considered cutoff scores of  $\geq 8$  as cases of anxiety including borderline and abnormal level based on the previous report [14].

We used a combined form of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 and the breast cancer specific module (BR-23), which has been translated into Korean and validated [16,17]. Symptoms (breast and arm) were measured using the 7 questions of the BR-23. The BR-23 has 23 items to assess the impact of common breast cancer treatment modalities (surgery, chemotherapy, radiotherapy, or hormonal treatment). It includes questions about body image, sexual functioning, sexual enjoyment, and future perspective for function and questions about systemic therapy side effects, breast symptoms, arm symptoms, and distress over hair loss (Supplementary Tables 3, 4). We used additional measured questions related to sociodemographic and clinical characteristics, including age, marital status, income, education, employment status, religion, stage, breast surgery type, and treatment received.

#### Statistical analysis

Differences in baseline demographical and clinical characteristics were compared by the severity of the anxiety group using chi-square tests for categorical variables and t-tests for continuous variables. Multilevel models were used to assess




Fig. 1. Study population. POD, postoperative day.

how the severity of anxiety affected the level of change in the symptom level over time and case-wise deletion was used for the missing data. This method is functionally the same as growth curve modeling or mixed-effects models. The models were adjusted for baseline demographical characteristics and clinical characteristics, as shown in Table 1. Full-information maximum likelihood estimation was used to directly compare the fit of the nested models to the data and to use all variable data, given the presence of missing data at random. All analyses were conducted using STATA 12.0 (StataCorp LP, College Station,

**Table 1.** Baseline characteristics of participants by severity of anxiety at the time of diagnosis

Characteristic	Total $(n = 411)$	Normal $(n = 228)$	Abnormal $(n = 183)$	P-value
Age (yr)				0.541
>40	86 (20.9)	47 (20.6)	39 (21.3)	
40–50	185 (45.0)	98 (43.0)	87 (47.5)	
50–60	118 (28.7)	68 (29.8)	50 (27.3)	
>60	22 (5.4)	15 (6.6)	7 (3.8)	
Marital status				0.144
Single	30 (7.3)	12 (5.3)	18 (9.8)	
Married	360 (87.8)	206 (90.7)	154 (84.2)	
Divorced/separated	7 (1.7)	2 (0.9)	5 (2.7)	
Widowed	13 (3.2)	7 (3.1)	6 (3.3)	
Income (monthly)	10 (012)	. (411)	5 (5.5)	0.817
Less than \$1,000	24 (5.9)	14 (6.1)	10 (5.5)	3.0.7
\$1,000–\$2,000	43 (10.5)	21 (9.2)	22 (12.1)	
\$2,000-\$3,000	67 (16.3)	37 (16.2)	30 (16.5)	
\$3,000–\$4,000	69 (16.8)	35 (15.4)	34 (18.7)	
\$4,000–\$4,000	85 (20.7)	50 (21.9)	35 (19.2)	
More than \$5,000	122 (29.8)	71 (31.1)	51 (28.0)	
Education	122 (23.0)	/ 1 (31.1)	J1 (20.0)	0.715
No education	1 (0.2)		1 (0.5)	0./13
Elementary school	1 (0.2) 22 (5.4)	- 14 (6.2)		
Middle school			8 (4.4)	
	30 (7.3)	17 (7.5)	13 (7.1)	
High school	166 (40.6)	93 (41.2)	73 (39.9)	
More than college	190 (46.5)	102 (45.1)	88 (48.1)	0.470
Employment status	101 (46 5)	102 (45.0)	00 (40 1)	0.470
Housewife	191 (46.5)	103 (45.2)	88 (48.1)	
Employed	87 (21.2)	55 (24.1)	32 (17.5)	
Leave of absence	51 (12.4)	26 (11.4)	25 (13.7)	
Self-employed	49 (11.9)	28 (12.3)	21 (11.5)	
Retired	24 (5.8)	13 (5.7)	11 (6.0)	
Student/military	9 (2.2)	3 (1.3)	6 (3.3)	
Religion				0.290
Christian	118 (28.8)	74 (32.6)	44 (24.0)	
Buddhist	99 (24.1)	53 (23.4)	46 (25.1)	
Catholic	51 (12.4)	23 (10.1)	28 (15.3)	
No religion	140 (34.1)	76 (33.5)	64 (35.0)	
Others	2 (0.5)	1 (0.4)	1 (0.6)	
Status of menstruation				0.402
Yes	270 (66.5)	145 (64.7)	125 (68.7)	
No	136 (33.5)	79 (35.3)	57 (31.3)	
Stage				0.211
0	27 (6.8)	17 (7.8)	10 (5.6)	
1	179 (45.1)	106 (48.4)	73 (41.0)	
2	146 (36.8)	76 (34.7)	70 (39.3)	
3	45 (11.3)	20 (9.1)	25 (14.0)	
Type of breast cancer surgery				0.685
Mastectomy	73 (17.9)	42 (18.6)	31 (17.0)	
Lumpectomy	335 (82.1)	184 (81.4)	151 (83.0)	



Table 1. Continued

Characteristic	Total $(n = 411)$	Normal $(n = 228)$	Abnormal $(n = 183)$	P-value
Adjuvant chemotherapy				0.010
Yes	284 (71.9)	146 (66.7)	138 (78.4)	
No	111 (28.1)	73 (33.3)	38 (21.6)	
Adjuvant radiotherapy				0.704
Yes	333 (84.3)	183 (84.3)	150 (85.7)	
No	59 (15.1)	34 (15.7)	25 (14.3)	
Adjuvant hormonal therapy				0.448
Yes	244 (63.5)	137 (65.2)	107 (61.5)	
No	140 (36.5)	73 (34.8)	67 (38.5)	

Values are presented as number (%).

Table 2. Prevalence of anxiety over time

Severity of anxiety	Preoperative (n = 411)	POD 2 wk (n = 374)	POD 3 mo (n = 336)	POD 6 mo (n = 327)	POD 12 mo (n = 315)
Normal (HADS 0–7)	228 (55.5)	278 (74.3)	251 (74.7)	233 (71.3)	211 (67.0)
Abnormal (HADS 8+)	183 (44.5)	96 (25.7)	85 (25.3)	94 (28.7)	104 (33.0)
HADS 8–10	94	57	51	55	67
HADS 11+	89	39	34	39	37

Values are presented as number (%).

POD, postoperative day; HADS, Hospital Anxiety Depression Scale.

TX). P < 0.05 was considered statistically significant.


#### **RESULTS**

# Characteristics of participants according to the preoperative level of anxiety

The characteristics of the 411 participants are listed in Table 1. A total of 183 patients (44.5%) showed abnormal levels of anxiety after diagnosis. The patients were regrouped into normal and abnormal groups based on the preoperative level of anxiety. We analyzed socioeconomic factors which could affect the baseline of anxiety; however, nothing was related with baseline anxiety. Age, marital status, income, statuses of education and employment, religion, and menstruation status were not associated with preoperative anxiety. Among clinical factors such as TNM stage and adjuvant therapy, nothing except adjuvant chemotherapy was related with baseline anxiety.

#### Temporal patterns of anxiety

Among 44.5% (183 of 411) of the patients who showed abnormal levels of anxiety preoperatively, 89 patients (48.6%) showed a high score of anxiety (more than 11). After surgery, about half of the patients who had an abnormal level of anxiety preoperatively returned to normal (from 44.5% to 25.7%) (Table 2). We could see the highest level of anxiety at diagnosis with improvement after surgery. As shown in Fig. 2, mean HADS-A



**Fig. 2.** Temporal patterns of anxiety symptom severity by mean anxiety dimension in Hospital Anxiety Depression Scale (HADS-A) score from diagnosis to 12 months. POD, postoperative day. \*P < 0.001.

score decreased significantly from 7.5 to 5.7 immediately after surgery. The HADS-A score was sustained during the follow-up period; though slightly elevated again at 12 months after the surgery when main adjuvant treatments were completed.

#### Factors of associated with persistent anxiety

A total of 250 patients with complete longitudinal data about anxiety were analyzed during the follow-up period. We classified these patients into 4 groups: Group 1 (normal), group 2 (newly developed anxiety), group 3 (resolved anxiety), and group 4 (persistent anxiety). Among the 141 patients who showed normal anxiety levels preoperatively, 22 (15.6%) developed anxiety symptoms late, at 12 months (group 2). Fiftyseven patients (52.3%) who showed abnormal levels of anxiety at baseline were normalized 12 months after surgery (group 3). Nonetheless, 29.6% (74 of 250) were still suffering from persistent (group 4) or newly developed (group 2) anxiety (Fig. 3). Fig. 4 shows the temporal pattern of anxiety of each group over time. According to the level of baseline anxiety, overall mean scores and pattern of change were different from each other.




Fig. 3. Prevalence of anxiety at postoperative day 12 months according to the baseline anxiety (n = 250).

Socioeconomic and clinicopathologic demographics were not associated with persistent anxiety in our data (Table 3). Pain, breast, and arm symptoms were significantly higher in the newly developed or persistent anxiety groups (groups 2 and 4), especially at the time of visits 4 (postoperative day [POD] 6 months) and 5 (POD 12 months).


# Comparison of anxiety level with regard to followup duration by breast cancer operation type

The anxiety level of the patients who underwent total mastectomy and partial mastectomy were not different (Fig. 5).

#### DISCUSSION

Previous studies have shown a diverse prevalence of anxiety, which depends on different criteria of the anxiety, diverse populations studied, differences in methodology used, and timing of measurement, ranging from about 20% to greater than 50% [1,2,8-12]. In this study, we could see a high prevalence of anxiety after the diagnosis of breast cancer. The percentage of patients with anxiety in the normal range was just over half (55.5%). Pathologic or clinical levels of anxiety (scores more than 11) were shown in 21.6% patients.

In this analysis, we examined the temporal pattern of anxiety starting from cancer diagnosis. Many previous studies for anxiety in breast cancer patients were assessed crosssectionally during the courses of treatment with different cohorts [10]. Few researchers have reported anxiety level in relation to time progression; however, they did not show the baseline anxiety from diagnosis [2,12,18]. Other previous studies demonstrated that level of anxiety was highest at diagnosis with improvement over time [19,20], consistent with






Fig. 4. Temporal pattern of anxiety symptom severity by mean anxiety dimension in Hospital Anxiety Depression Scale (HADS-A) score of each group over time (group 1, normal; group 2, newly developed anxiety; group 3, resolved anxiety; and group 4, persistent anxiety). POD, postoperative day.



Table 3. Factors associated with persistent anxiety

Characteristic	Group 1 (n = 119)	Group 2 (n = 22)	Group 3 (n = 57)	Group 4 (n = 52)	P-value
Age (yr)					0.788
>40	26 (21.8)	6 (27.3)	12 (21.1)	13 (25.0)	
40–50	50 (42.0)	9 (40.9)	30 (52.6)	22 (42.3)	
50-60	39 (32.8)	5 (22.7)	13 (22.8)	16 (30.8)	
>60	4 (4.4)	2 (9.1)	2 (3.5)	1 (1.9)	
Marital status					0.560
Single	7 (5.9)	1 (4.6)	8 (14.0)	7 (13.5)	
Married	106 (89.1)	21 (95.4)	47 (82.5)	41 (78.8)	
Divorced/separated	2 (1.7)	-	1 (1.8)	2 (3.9)	
Widowed	4 (3.4)	-	1 (1.7)	2 (3.8)	
Income (monthly)					0.737
Less than \$1,000	6 (5.0)	1 (4.6)	2 (3.5)	3 (5.9)	
\$1,000-\$2,000	10 (8.4)	3 (13.6)	6 (10.5)	7 (13.7)	
\$2,000-\$3,000	21 (17.6)	1 (4.6)	11 (19.3)	5 (9.8)	
\$3,000-\$4,000	22 (18.5)	3 (13.6)	12 (21.1)	14 (27.5)	
\$4,000-\$5,000	24 (20.2)	4 (18.2)	13 (22.8)	7 (13.7)	
More than \$5,000	36 (30.3)	10 (45.4)	13 (22.8)	15 (29.4)	
Education					0.641
No education	-	-	-	-	
Elementary school	4 (3.4)	-	4 (7.0)	4 (7.7)	
Middle school	11 (9.2)	1 (4.6)	2 (3.5)	2 (3.8)	
High school	52 (43.7)	9 (40.9)	22 (38.6)	21 (40.4)	
More than college	52 (43.7)	12 (54.5)	29 (50.9)	25 (48.1)	
Employment status					0.311
Housewife	60 (50.4)	12 (54.6)	23 (40.3)	26 (50.0)	
Employed	24 (20.2)	7 (31.8)	11 (19.3)	12 (23.1)	
Leave of absence	18 (15.1)	-	7 (12.3)	8 (15.4)	
Self-employed	9 (7.6)	3 (13.6)	9 (15.8)	2 (3.8)	
Retired	6 (5.0)	-	3 (5.3)	3 (5.8)	
Student/military	2 (1.7)	-	4 (7.0)	1 (1.9)	
Religion	,			( ,	0.310
Christian	42 (35.3)	6 (27.3)	15 (26.3)	12 (23.1)	0.0.0
Buddhist	31 (26.0)	5 (22.7)	10 (17.5)	18 (34.6)	
Catholic	12 (10.1)	2 (9.1)	12 (21.1)	6 (11.5)	
No religion	34 (28.6)	9 (40.9)	19 (33.3)	16 (30.8)	
Others	5+ (20.0) -	- -	1 (1.8)	-	
Stage			1 (1.0)		0.159
0	4 (3.5)	1 (4.6)	5 (8.8)	1 (1.9)	0.133
1	59 (51.3)	15 (68.2)	22 (38.6)	25 (48.1)	
2	43 (37.4)	3 (13.6)	20 (35.1)	18 (34.6)	
3	9 (7.8)	3 (13.6)	10 (17.5)	8 (15.4)	
Status of menstruation	5 (7.0)	5 (15.0)	10 (17.3)	0 (13.4)	0.639
Yes	78 (66.7)	14 (63.6)	42 (73.7)	32 (62.7)	0.033
No	39 (33.3)	8 (36.4)	15 (26.3)	19 (37.3)	
Type of breast cancer surgery	55 (55.5)	0 (30. <del>4</del> )	13 (20.3)	15 (37.3)	0.530
Mastectomy	15 (12.6)	4 (18.2)	12 (21.1)	8 (15.4)	0.550
Lumpectomy			45 (78.9)		
	104 (87.4)	18 (81.8)	45 (70.9)	44 (84.6)	0.101
Adjuvant chemotherapy	22 (27 1)	12 (45 5)	4E (79.0)	41 (90 4)	0.101
Yes	32 (27.1)	12 (45.5)	45 (78.9)	41 (80.4)	
No	86 (72.9)	10 (54.5)	12 (21.1)	10 (19.6)	0.035
Adjuvant radiotherapy Yes	104 (90.4)	20 (90.9)	50 (87.7)	45 (88.2)	0.935

Table 3. Continued

Characteristic	Group 1 (n = 119)	Group 2 (n = 22)	Group 3 (n = 57)	Group 4 $(n = 52)$	P-value
Adjuvant hormonal therapy					0.580
Yes	73 (65.2)	15 (68.2)	32 (57.1)	29 (56.9)	
No	39 (34.8)	7 (31.8)	24 (42.9)	22 (43.1)	
Pain					
Visit 1	$10.3 \pm 1.2$	$15.9 \pm 3.0$	$16.9 \pm 2.5$	$19.6 \pm 2.0$	0.001
Visit 2	$25.8 \pm 1.9$	$31.1 \pm 3.1$	$34.5 \pm 2.9$	$36.2 \pm 3.1$	0.008
Visit 3	$17.7 \pm 1.7$	$20 \pm 3.9$	$26.2 \pm 3.1$	$31 \pm 3.0$	< 0.001
Visit 4	$18.8 \pm 1.9$	$25 \pm 3.7$	$20.2 \pm 2.7$	$35.9 \pm 3.6$	< 0.001
Visit 5	$20.5 \pm 3.5$	$29.5 \pm 5.1$	$19.0 \pm 2.4$	$27.1 \pm 2.5$	0.299
Breast symptom					
Visit 1	$11.2 \pm 1.2$	$13.6 \pm 3.9$	$15.7 \pm 1.4$	$16.7 \pm 2.1$	0.065
Visit 2	$21.5 \pm 1.3$	$25.7 \pm 3.8$	$27.3 \pm 2.5$	$30.4 \pm 2.4$	0.007
Visit 3	$17.1 \pm 1.3$	$23.3 \pm 3.2$	$18.4 \pm 1.9$	$20.7 \pm 2.5$	0.241
Visit 4	$18.7 \pm 1.4$	$29.2 \pm 3.9$	$19.8 \pm 2.1$	$27.7 \pm 2.7$	0.002
Visit 5	$18.1 \pm 1.7$	$28.8 \pm 4.5$	$19.6 \pm 2.0$	$27.2 \pm 2.1$	0.002
Arm symptom					
Visit 1	$9.4 \pm 1.1$	$13.2 \pm 3.5$	$14.1 \pm 2.3$	$14.4 \pm 2.6$	0.118
Visit 2	$27.2 \pm 1.7$	$27.3 \pm 3.2$	$34.5 \pm 3.1$	$35.2 \pm 3.3$	0.041
Visit 3	$18.2 \pm 1.7$	$23.3 \pm 3.7$	$21.8 \pm 2.6$	$24 \pm 2.5$	0.220
Visit 4	$23.1 \pm 1.9$	$30.7 \pm 5.6$	$26.9 \pm 2.8$	$30.1 \pm 2.9$	0.161
Visit 5	$21.0 \pm 1.8$	$35.8 \pm 4.9$	$23.6 \pm 3.0$	$32.0 \pm 3.1$	0.001

Values are presented as number (%) or mean  $\pm$  standard error.

Group 1, normal; group 2, newly developed anxiety; group 3, resolved anxiety; group 4, persistent anxiety.




Fig. 5. Comparison of anxiety level with regard to follow-up duration by breast cancer operation type. HADS-A, anxiety dimension in Hospital Anxiety Depression Scale; POD, postoperative day.

our data. However, these studies did not assess the anxiety level at immediate postoperative period, and could not show the effect of surgery itself on the anxiety.

Several studies showed distress trajectories including anxiety after cancer diagnosis [18]. Henselmans et al. [21] found that most breast cancer survivors within the first year postdiagnosis

experienced no psychological distress (36.3%) or recovered to normal after completion of active treatment (33.3%), but small percentages of breast cancer survivors became distressed in the re-entry and survivorship phase (15.2%) or experienced persistent distress (15.2%) in the first year after breast cancer diagnosis. These are comparable with our study results in which 8.8% of patients became newly distressed in the re-entry periods (group 2) and 20.8% showed chronic anxiety (group 4) at month 12.

During the observation period of our cohort, there were 2 distinctive features. The first was rapid relief of anxiety after surgery. Patients were the most anxious before surgery, and this level of anxiety was sharply decreased after surgery. Understandably, this phenomenon was probably the fear of uncertainty about the cancer itself, treatment process, and outcomes. It could simply that surgery is a main relieving factor of anxiety; however, conversely, surgery itself is also a primary fear for patients after cancer diagnosis. Secondly, we could see the second rising of anxiety (re-entry) at 12 months. Most main adjuvant therapies were finished and the patients entered follow-up periods at this time. Several studies showed that anxiety generally decreased with time during the treatment period [8,12,18,22]. However, after completion of the treatment, the patients confront worries about leaving the health care system, uncertainty about the future, and the fear of recurrence [23-25], and these could raise distress levels as in our results.



There have been many reports about the psychological distress associated factors in breast cancer [8-12,22,23,26]. Unlike these studies, in our study, socioeconomic factors, younger age, stage, social support, and mastectomy did not elevate anxiety. Adjuvant chemotherapy was preoperatively thought to be a risk factor of anxiety; however, after completion of chemotherapy, chemotherapy was not associated with elevated levels of anxiety. In our analysis, pain, and breast and arm symptoms were associated with persistent anxiety as in previous reports in which pain influences anxiety [8,12,22].

There are some limitations to this study. This is a preliminary report with short-term follow-up data. Long-term follow-up results could provide the evidence and the reason for the reentry phenomenon. In addition to this, baseline distress, which was assessed preoperatively but not before diagnosis, did not reflect the real baseline (normal psychological) status of each person. If we have control cohorts (general population), the effect of breast cancer diagnosis on anxiety could be assessed more objectively. However, considering the result of previous research reporting that the prevalence of anxiety using HADS was 32.2% in generally healthy women [27], the breast cancer patients in our study seemed to suffer from anxiety more frequently after diagnosis. We needed also more information about previous mental health status because a past history of or pre-existing anxiety and/or depression before cancer diagnosis was known as an important predictor of anxiety [19,28]. Regardless of these limitations, we have several important strengths. First is the design of this study. This is a prospective longitudinal study, and we could assess the psychological status from the preoperative period to 12 months. Also, our research was performed at clearly defined time points, including preoperative and immediate postoperative periods. Several prospective studies had much heterogeneity in assessment timing and did not assess the preoperative status.

In conclusion, anxiety disorder was common in patients who were diagnosed with breast cancer (44.5%). Surgery was a main relieving factor of anxiety and patients who finished their main adjuvant treatments experienced renewed anxiety. Surgeons should be the main detectors and care-givers for psychological

distress in breast cancer patients during the time after diagnosis and completion of adjuvant therapy. To reduce persistent anxiety, taking care of physical symptoms is important.

## **SUPPLEMENTARY MATERIALS**

Supplementary questionnaires can be found via https://doi.org/10.4174/astr.2020.98.5.215.

#### **ACKNOWLEDGEMENTS**

#### **Fund/Grant Support**

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2017R1E1A1A0107764214).

#### **Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

#### **ORCID iD**

Jiyoung Kim: https://orcid.org/0000-0003-0685-1722
Juhee Cho: https://orcid.org/0000-0001-9081-0266
Se Kyung Lee: https://orcid.org/0000-0003-1630-1783
Eun-Kyung Choi: https://orcid.org/0000-0002-7915-332X
Im-Ryung Kim: https://orcid.org/0000-0002-7515-347X
Jeong Eon Lee: https://orcid.org/0000-0003-0037-2456
Seok Won Kim: https://orcid.org/0000-0002-6130-7570
Seok-Jin Nam: https://orcid.org/0000-0003-1072-8954

#### **Author Contribution**

Conceptualization: JK, JC, SKL, JEL, SWK, SJN

Formal Analysis: JC, EKC, IRK

Investigation: JK, EKC, IRK, SKL, JEL, SWK, SJN

Methodology: JC, EKC, IRK, SKL Project Administration: JC, SKL

Writing – Original Draft: JK, SKL

Writing - Review & Editing: JC, SKL, EKC, IRK, JEL, SWK, SJN

### **REFERENCES**

- Stark D, Kiely M, Smith A, Velikova G, House A, Selby P. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002;20:3137-48.
- 2. Taira N, Shimozuma K, Shiroiwa
- T. Ohsumi S. Kuroi K. Saji S. et al. Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat 2011;128:735-47.
- 3. DiMatteo MR. Lepper HS. Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7.

- 4. Greer JA, Pirl WF, Park ER, Lynch TJ, Temel JS. Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res 2008;65:549-
- 5. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat 2007;105:209-19.
- 6. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7:102.
- 7. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009;115:5349-61.
- 8. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005;330:702.
- 9. So WK, Marsh G, Ling WM, Leung FY, Lo JC, Yeung M, et al. Anxiety, depression and quality of life among Chinese breast cancer patients during adjuvant therapy. Eur J Oncol Nurs 2010;14:17-22.
- 10. Ho SS, So WK, Leung DY, Lai ET, Chan CW. Anxiety, depression and quality of life in Chinese women with breast cancer during and after treatment: a comparative evaluation. Eur J Oncol Nurs 2013;17:877-
- 11. Schubart JR, Emerich M, Farnan M, Stanley Smith J, Kauffman GL, Kass RB. Screening for psychological distress in surgical breast cancer patients. Ann Surg Oncol 2014:21:3348-53.
- 12. Saboonchi F. Petersson LM. Wennman-Larsen A, Alexanderson K, Brannstrom R, Vaez M. Changes in caseness of anxiety and depression in breast cancer patients during the first year following surgery: patterns of transiency and severity of

- the distress response. Eur J Oncol Nurs 2014:18:598-604.
- 13. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983:67:361-70.
- 14. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 2002;52:69-77.
- 15. Oh SM, Min KJ, Park DB. A study on the standardization of the hospital anxiety and depression scale for koreans: a comparison of normal, depressed and anxious groups. J Korean Neuropsychiatr Assoc 1999;38:289-96.
- 16. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756-68.
- 17. Yun YH, Bae SH, Kang IO, Shin KH, Lee R, Kwon SI, et al. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer 2004;12:441-5.
- 18. Boyes AW, Girgis A, D'Este CA, Zucca AC, Lecathelinais C, Carey ML. Prevalence and predictors of the short-term trajectory of anxiety and depression in the first year after a cancer diagnosis: a populationbased longitudinal study. J Clin Oncol 2013;31:2724-9.
- 19. Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M. Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 2015;23:2215-24.
- 20. Kyranou M, Puntillo K, Dunn LB, Aouizerat BE, Paul SM, Cooper BA, et al. Predictors of initial levels and trajectories of anxiety in women before and for 6 months after breast cancer surgery.

- Cancer Nurs 2014;37:406-17.
- 21. Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol 2010;29:160-8.
- 22. Schwarz R, Krauss O, Hockel M, Meyer A, Zenger M, Hinz A. The course of anxiety and depression in patients with breast cancer and gynaecological cancer. Breast Care (Basel) 2008:3:417-22.
- 23. Karakoyun-Celik O, Gorken I, Sahin S, Orcin E, Alanyali H, Kinay M. Depression and anxiety levels in woman under follow-up for breast cancer: relationship to coping with cancer and quality of life. Med Oncol 2010:27:108-13.
- 24. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a systematic review of quantitative studies. Psychooncology 2013;22:1-11.
- 25. Jefford M, Karahalios E, Pollard A, Baravelli C, Carey M, Franklin J, et al. Survivorship issues following treatment completion--results from focus groups with Australian cancer survivors and health professionals. J Cancer Surviv 2008;2:20-32.
- 26. Yang H, Brand JS, Fang F, Chiesa F, Johansson AL, Hall P, et al. Timedependent risk of depression, anxiety, and stress-related disorders in patients with invasive and in situ breast cancer. Int J Cancer 2017;140:841-52.
- 27. Kim SH, Kang S, Kim YM, Kim BG, Seong SJ, Cha SD, et al. Prevalence and predictors of anxiety and depression among cervical cancer survivors in Korea. Int J Gynecol Cancer 2010;20:1017-24.
- 28. Stafford L, Komiti A, Bousman C, Judd F, Gibson P, Mann GB, et al. Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. Breast 2016;26:100-5.